TrialInvestigational new drugs2022

A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma.

Daniel H Ahn et al.PubMed ↗Publisher ↗

No numbers read from the abstract.